[{"data":1,"prerenderedAt":151},["ShallowReactive",2],{"drug-dexrazoxane":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":22,"regimens":37,"contraindications":58,"warnings":68,"renal":76,"monitoring":77,"interactions":78,"review":79,"examples":82,"atc":83,"iran":85,"usApproval":92,"links":98,"populations":115},"dexrazoxane",1,{"fa":7,"en":8},"دکس‌رازوکسان","Dexrazoxane","various",{"fa":11,"en":12},"محافظ قلب در برابر آنتراسایکلین","Anthracycline cardioprotectant",[14],{"name":15,"market":16},"Zinecard","US",[18,19,20,21],"zinecard","totect","زینکارد","دکسرازوکسان",[23],{"id":24,"form":25,"route":26,"label":27,"concentration":28,"markets":32,"refs":33},"vial-250","powder-for-injection","iv","250 mg vial",{"amount":29,"unit":30,"perUnit":31},250,"mg","vial",[16],[34],{"source":35,"section":36},"fda-dexrazoxane","3",[38],{"id":39,"disease":40,"label":41,"population":44,"type":48,"unit":30,"dose":49,"refs":53},"cardio","breast-cancer",{"fa":42,"en":43},"کاهش کاردیومیوپاتی دوکسوروبیسین — نسبت ۱۰ به ۱ با دوز دوکسوروبیسین (مثلاً ۵۰۰ mg\u002Fm² برای ۵۰ mg\u002Fm²)","Reduce doxorubicin cardiomyopathy — 10:1 ratio to the doxorubicin dose (e.g. 500 mg\u002Fm² for 50 mg\u002Fm²)",{"minAge":45},{"value":46,"unit":47},18,"year","notCalculated",{"reason":50},{"fa":51,"en":52},"دوز = ۱۰ برابر دوز دوکسوروبیسین (mg\u002Fm²)؛ تزریق آهسته یا انفوزیون سریع؛ دوکسوروبیسین ظرف ۳۰ دقیقه پس از پایان آن (هرگز قبل). ClCr زیر ۴۰: نسبت ۵ به ۱.","Dose = 10 × the doxorubicin dose (mg\u002Fm²); slow push or rapid drip; give doxorubicin within 30 min after it ends (never before). CrCl \u003C40: 5:1 ratio.",[54,56],{"source":35,"section":55},"2.1",{"source":35,"section":57},"2.2",[59],{"id":60,"severity":61,"text":62,"refs":65},"ci","block",{"fa":63,"en":64},"همراه رژیم‌های غیرآنتراسایکلینی نه.","Do not use with non-anthracycline regimens.",[66],{"source":35,"section":67},"4",[69],{"text":70,"refs":73},{"fa":71,"en":72},"تشدید سرکوب مغز استخوان؛ سمیت قلبی همچنان ممکن؛ بدخیمی ثانویه؛ سمیت جنینی.","Added myelosuppression; cardiac toxicity still possible; secondary malignancy; embryo-fetal toxicity.",[74],{"source":35,"section":75},"5",[],[],[],{"status":80,"reviewer":81,"date":81},"unverified",null,[],[84],"V03AF02",{"status":86,"refs":87},"registered",[88],{"source":89,"section":90,"url":91},"darooyab-generic","G-1947\u002FDexrazoxane","https:\u002F\u002Fwww.darooyab.ir\u002FG-1947\u002FDexrazoxane",{"kind":93,"refs":94,"id":97},"ANDA",[95],{"source":35,"section":96},"SPL approval \u002F marketing category","ANDA200752",[99,102,106,110,113],{"kind":100,"url":101,"label":97},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=200752",{"kind":103,"url":104,"label":105},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=cb72203a-0b09-42d5-bf51-7f479feb3adb","FDA Dexrazoxane",{"kind":107,"url":108,"label":109},"medlineplus","https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa609010.html","Dexrazoxane Injection",{"kind":111,"url":112,"label":84},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=V03AF02",{"kind":114,"url":91,"label":8},"darooyab",{"pregnancy":116,"lactation":125,"pediatric":134,"geriatric":143},{"level":117,"text":118,"quote":121,"refs":122},"avoid",{"fa":119,"en":120},"برچسب: می‌تواند به جنین آسیب بزند. در بارداری خطرناک است.","Label: can cause fetal harm. Dangerous in pregnancy.","Risk Summary Dexrazoxane can cause fetal harm when administered to pregnant women.",[123],{"source":35,"section":124},"8.1",{"level":126,"text":127,"quote":130,"refs":131},"caution",{"fa":128,"en":129},"برچسب: در شیردهی با احتیاط؛ متن برچسب را ببینید.","Label: use with caution while breastfeeding; see the label text.","Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from dexrazoxane, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.",[132],{"source":35,"section":133},"8.3",{"level":135,"text":136,"quote":139,"refs":140},"not-established",{"fa":137,"en":138},"برچسب: ایمنی و اثربخشی در کودکان ثابت نشده است.","Label: safety and effectiveness in children have not been established.","The safety and effectiveness of dexrazoxane in pediatric patients have not been established [see Warnings and Precautions (5.4) ] .",[141],{"source":35,"section":142},"8.4",{"level":126,"text":144,"quote":147,"refs":148},{"fa":145,"en":146},"برچسب: در سالمندان با احتیاط و معمولاً از دوز پایین شروع شود.","Label: use with caution in older adults, usually starting at the low end of the dose range.","In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.",[149],{"source":35,"section":150},"8.5",1792444716788]